Cargando…
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
BACKGROUND: Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been investigated using different antibody clones, staining protoco...
Autores principales: | Zajac, Magdalena, Scott, Marietta, Ratcliffe, Marianne, Scorer, Paul, Barker, Craig, Al-Masri, Hytham, Rebelatto, Marlon C., Walker, Jill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720992/ https://www.ncbi.nlm.nih.gov/pubmed/31477145 http://dx.doi.org/10.1186/s13000-019-0873-6 |
Ejemplares similares
-
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
por: Scorer, Paul, et al.
Publicado: (2018) -
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry
por: Duncan, David Jonathan, et al.
Publicado: (2019) -
Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020) -
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review
por: Sherwood, James, et al.
Publicado: (2015) -
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
por: Widmaier, Moritz, et al.
Publicado: (2019)